Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22292133)

  • 1. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.
    Dumaz N
    Small GTPases; 2011 Sep; 2(5):289-292. PubMed ID: 22292133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
    Marquette A; André J; Bagot M; Bensussan A; Dumaz N
    Nat Struct Mol Biol; 2011 May; 18(5):584-91. PubMed ID: 21478863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
    Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R
    Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2.
    Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
    Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
    Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
    Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
    PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
    Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active Ras induces heterodimerization of cRaf and BRaf.
    Weber CK; Slupsky JR; Kalmes HA; Rapp UR
    Cancer Res; 2001 May; 61(9):3595-8. PubMed ID: 11325826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
    Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
    BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization.
    Yu A; Nguyen DH; Nguyen TJ; Wang Z
    J Biol Chem; 2023 Oct; 299(10):105188. PubMed ID: 37625591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.